Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06296966 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye
A Phase 2 study of Dry Eye, sponsored by Vanda Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT06296966 is a Phase 2 study of Dry Eye that is actively recruiting participants, run by Vanda Pharmaceuticals. The registered enrollment target is 40 participants, below the 95-participant average among 41 other Dry Eye trials with a reported enrollment target (58% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06296966, a Phase 2 study of Dry Eye, is actively recruiting participants, sponsored by Vanda Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the safety and efficacy of VSJ-110 compared to placebo in the treatment of dry eye.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG VSJ-110
Study Locations (1)
Massachusetts
- Vanda Investigational Site - Andover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2024-02-29 |
| Est. Completion | 2024-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06296966
The ClinicalTrials.gov registry entry for NCT06296966 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 95-participant average among 41 other Dry Eye trials with a reported enrollment target (58% lower). The listed sponsor is Vanda Pharmaceuticals, which has 68 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dry Eye appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06296966 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06296966 about?
NCT06296966 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye". The purpose of this study is to determine the safety and efficacy of VSJ-110 compared to placebo in the treatment of dry eye.
What is the current status of trial NCT06296966?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2024-02-29. Estimated completion is 2024-07.
What conditions does trial NCT06296966 study?
This clinical trial studies the following conditions: Dry Eye.
What interventions are being tested in trial NCT06296966?
The interventions under investigation include: Placebo (DRUG), VSJ-110 (DRUG).
Who is sponsoring clinical trial NCT06296966?
This trial is sponsored by Vanda Pharmaceuticals, which has 68 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06296966 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Eye
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye
RECRUITING · Phase 2
-
Phase 2b Controlled Study of Dosing Techniques - Part B
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Assess the Safety and Efficacy of ECF843 vs Vehicle in Subjects With Dry Eye Disease
COMPLETED · Phase 2
-
An 8-week Study to Evaluate Safety and Efficacy of NGF Eye Drops Solution Versus Vehicle in Patients With Dry Eye
COMPLETED · Phase 2
-
Can Pregabalin Reduce the Frequency and Severity of Dry Eye Symptoms After Laser-assisted in Situ Keratomileusis?
COMPLETED · Phase 2
-
Treatment of Patients With Blepharitis and Facial Rosacea
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.